Primer composition and kit for detecting drug-resistant gene of sepsis
By designing detection primer sets for multiple drug-resistant genes and using nucleic acid amplification chips, combining LAMP method and internal standard solution, the problem of inconsistent detection efficiency of drug-resistant genes in the existing technology has been solved, and the twelve sepsis has been achieved. The rapid, efficient and specific detection of dysfunction-resistant genes improves the stability and accuracy of the detection.
Patent Information
- Application Number
- CN202411561718.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-11-05
- Publication Date
- 2024-12-03
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The existing LAMP technology is difficult to achieve stable, efficient and high specific detection of more than ten major drug-resistant genes in sepsis resistance gene detection, mainly due to the inconsistent amplification efficiency due to the difference in primer composition loop efficiency.
A primer composition for drug-resistant gene detection of sepsis is designed, including detection of drug-resistant genes such as KPC, IMP, NDM, Oxa-48-like, VIM, GES, aac, aph, ant, armA, mecA and mecC. The primer set, combined with the nucleic acid amplification chip and specific reaction reagent formula, was used to amplify nucleic acid under constant temperature of 60-65°C by LAMP method, and the internal standard and control solution were used to ensure the accuracy of the detection.
It has achieved rapid, efficient and specific detection of twelve sepsis-resistant genes, reduced detection costs, improved detection stability and accuracy, and identified drug-resistant genes within 1 hour, thus helping in clinical treatment.
Smart Images

Figure CN119061136A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of gene detection kits and relates to a primer composition and a kit for detecting sepsis resistance genes. Background Art
[0002] Sepsis is a systemic inflammatory response syndrome caused by infection, which is common in patients with severe trauma or infectious diseases. The causes of the disease include infections caused by bacteria, fungi, viruses and parasites, which lead to the body's inflammatory response and immune regulation imbalance.
[0003] The pathogenic microorganisms that cause sepsis mainly include Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter cloacae, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus aureus and other Gram-negative rods. These pathogenic microorganisms often contain drug-resistant genes. The drug-resistant genes in sepsis pathogens are a major challenge in the treatment of sepsis because they can lead to failure of antibiotic treatment. It is necessary to first determine the drug-resistant genes contained in the sample during treatment, and then choose the appropriate drugs to achieve the best therapeutic effect.
[0004] Loop-mediated isothermal amplification (LAMP) is an efficient, simple, and highly specific nucleic acid amplification technology that can be completed under constant temperature conditions without the need for thermal cycling equipment. This technology uses specific primers and strand-displacing DNA polymerase to perform efficient and rapid gene amplification and detection under isothermal conditions. LAMP technology is widely used in pathogen detection, food safety testing and other fields.
[0005] However, the current LAMP technology still has some problems in practical applications, such as non-specific amplification of primers, poor stability of the reaction system, etc., and it is difficult to achieve high-throughput detection in a true sense.
[0006] Due to the above problems, the current detection technology for sepsis resistance genes is difficult to achieve stable, efficient and highly specific detection of more than ten major sepsis resistance genes at the same time. This is because the isothermal amplification circularization efficiency of different primer sets varies greatly, making it difficult to achieve similar amplification efficiency under the same system conditions. Summary of the invention
[0007] The object of the present invention is to provide a sepsis resistance gene detection primer composition and a kit, which have the characteristics of being able to simultaneously perform stable, efficient and highly specific detection on more than ten types of sepsis resistance genes.
[0008] The purpose of the present invention can be achieved through the following technical solutions: A sepsis drug-resistant gene detection primer composition, comprising a detection primer set of carbapenem-resistant genes: KPC, IMP, NDM, Oxa-48-like, VIM and GES, aminoglycoside-resistant genes: aac, aph, ant and armA, and methicillin-resistant genes: mecA and mecC, wherein the detection primer set consists of one or more of an upstream loop primer LF or a downstream loop primer LB, except for the armA and mecC detection primer sets, which do not include the LF and the LB, an upstream outer primer F3, a downstream outer primer B3, an upstream inner primer FIP and a downstream inner primer BIP, and the nucleotide sequence is as follows: KPC detection primer set: SEQ ID NO: 1 to SEQ ID NO: 5; IMP detection primer set: SEQ ID NO: 6 to SEQ ID NO: 10; NDM detection primer set: SEQ ID NO: 11 to SEQ ID NO: 16; Oxa-48-like detection primer set: SEQ ID NO: 17 to SEQ ID NO: 21; VIM detection primer set: SEQ ID NO: 22 to SEQ ID NO: 26; GES detection primer set: SEQ ID NO: 27 to SEQ ID NO: 31; aac detection primer set: SEQ ID NO: 32 to SEQ ID NO: 36; aph detection primer set: SEQ ID NO:37 to SEQ ID NO:41; Ant detection primer set: SEQ ID NO: 42 to SEQ ID NO: 47; armA detection primer set: SEQ ID NO:48 to SEQ ID NO:51; mecA detection primer set: SEQ ID NO: 52 to SEQ ID NO: 56; mecC detection primer set: SEQ ID NO:57 to SEQ ID NO:60.
[0009] Preferably, it also includes internal standard gene HBB detection primers, the nucleotide sequences of which are as follows: SEQ ID NO:61 to SEQ ID NO:66.
[0010] A sepsis resistance gene detection kit comprises 6 chips, 5 mL of lysate, 0.5 mL of internal standard solution, 1 mL of negative control solution, 1 mL of positive control solution and 12 chip sealing films, wherein the chip is provided with a plurality of reaction pools, each of which is embedded with one of the sepsis resistance gene detection primer compositions according to claim 1.
[0011] Preferably, the ratio of the detection primer set embedded in the reaction pool is F3:B3:FIP:BIP:LF:LB is 1:1:5~8:5~8:3:3.
[0012] Preferably, the chip is embedded with reaction reagents, which include freeze-dried proteinase K, 100-400 μL of a first cleaning solution, 100-400 μL of a second cleaning solution, 60-120 μL of an elution solution, and a constant temperature amplification reaction freeze-dried ball.
[0013] Preferably, the first cleaning solution is composed of sodium chloride NaCl with a concentration of 0.01-0.2 M and isopropanol with a percentage concentration of 20-60%, the second cleaning solution is anhydrous ethanol with a percentage concentration of 40-80%, and the eluent is 1×TE Buffer.
[0014] Preferably, the isothermal amplification reaction freeze-dried ball consists of a 10 mM deoxyribonucleoside triphosphate dNTP, a 5% bovine serum albumin BSA, a 5 M magnesium sulfate MgSO4, a 100 μM fluorescent dye, a 5 M betaine and an 8 U / μL Bst DNA polymerase, and the preparation ratio is 2:3~5:1:1:2~4:1~3. The amplification concentration of the Bst DNA polymerase is 0.3~3 U / μL.
[0015] Preferably, the lysate consists of 50-100 mM ethylenediaminetetraacetic acid (EDTA), 3-5 M guanidine hydrochloride, 10-20% Tween-20, and 1-5% sodium dodecyl sulfate (SDS).
[0016] Preferably, the internal standard solution is a glycerol bacterial solution containing an internal standard gene HBB fragment, the negative control solution is physiological saline, and the positive control solution is a mixed glycerol bacterial solution containing one or more of the carbapenem-resistant genes: KPC, IMP, NDM, Oxa-48-like, VIM and GES, the aminoglycoside-resistant genes: aac, aph, ant and armA, and the methicillin-resistant genes: mecA and mecC fragments.
[0017] The armA detection primer set and the mecC detection primer set in the present invention do not include the upstream loop primer LF and the downstream loop primer LB. These two primer sets are composed of the upstream outer primer F3, the downstream outer primer B3, the upstream inner primer FIP and the downstream inner primer BIP. The remaining 10 detection primer sets are composed of one or more of the upstream loop primer LF or the downstream loop primer LB, the upstream outer primer F3, the downstream outer primer B3, the upstream inner primer FIP and the downstream inner primer BIP.
[0018] The present invention uses the LAMP method to perform nucleic acid amplification, which can be performed at a constant temperature of 60 to 65°C. The amplification speed is fast, and the time from reaction to detection only takes 15 to 60 minutes. It does not require complex equipment, is easy to operate, and improves detection efficiency.
[0019] The present invention designs primer combinations for 6 regions of 12 sepsis resistance genes, specifically identifies multiple independent regions on each resistance gene, improves the specificity and sensitivity of resistance gene detection, ensures the accuracy of the test results, and can quickly identify resistance genes within 1 hour, so that the most suitable drug can be selected for the resistance genes, which is of great significance for clinical treatment.
[0020] The chip used in the present invention is an integrated microfluidic chip for nucleic acid detection, and the chip includes a mixing pool, a sample addition hole, a first liquid capsule, a second liquid capsule, a third liquid capsule, a sample pool, an adsorption column, a waste liquid pool, an internal standard pool, a negative pool, a reserved pool and a reaction pool; freeze-dried proteinase K is embedded in the sample pool; a first cleaning liquid is embedded in the first liquid capsule, a second cleaning liquid is embedded in the second liquid capsule, an elution liquid is embedded in the third liquid capsule, and different reaction reagents are embedded in the three liquid capsules respectively, and the reagents will not contaminate each other before the experimental operation is performed, thereby ensuring the accuracy of the reaction; a puncture mechanism is arranged under the liquid capsule, and the liquid capsule can be released by pressing down the bottom of the liquid capsule to puncture it. The chip is provided with a mixing pool, in which is embedded a constant temperature amplification reaction freeze-dried ball, so that the sample and the reaction reagent can be fully mixed to ensure the stability of the subsequent constant temperature reaction; the mixed sample is centrifuged and injected into the reaction pool in sequence to ensure that the amount of samples entering each reaction pool is uniform, thereby improving the stability and accuracy of the detection; the internal standard pool is embedded with an internal standard gene HBB detection primer, and the reaction pool is provided with multiple ones, each of which is embedded with one of twelve sepsis resistance gene detection primer groups. The chip can detect twelve sepsis resistance genes at the same time, has a large detection throughput, high efficiency, and greatly reduces the average cost of detecting a single resistance gene.
[0021] The present invention is provided with an internal standard solution, a negative control solution and a positive control solution, and an internal standard pool and a negative pool are provided, so that the nucleic acid extraction and isothermal amplification processes can be fully monitored, the accuracy of sample detection is ensured, and inaccurate detection results caused by reagent problems are prevented.
[0022] The samples used in the present invention may be blood, sputum and bronchoalveolar lavage fluid. Sputum and bronchoalveolar lavage fluid samples often contain lumps, which affect the detection results. For sputum and bronchoalveolar lavage fluid samples, the present invention only requires a small amount of sample and liquefies the sample by NaOH to reduce influencing factors. There are many interfering substances in the blood sample and the pathogen concentration is low, which will affect the detection results. The present invention specifically enriches the pathogens in the blood sample by mannose binding lectin, increases the pathogen concentration, and optimizes the overall reaction system, thereby improving the sensitivity of the detection. The detection sensitivity for each pathogenic microorganism is high, all reaching 100 copies / mL.
[0023] Beneficial effects of the present invention: The present invention can specifically identify multiple independent regions on each drug-resistant gene, improve the specificity and sensitivity of drug-resistant gene detection, ensure the accuracy of the detection results, use the LAMP method for nucleic acid amplification, which is simple to operate and has high detection efficiency. It can quickly identify drug-resistant genes within 1 hour, so that the most suitable drug can be selected for the drug-resistant gene, which is of great significance for clinical treatment; The chip used in the present invention is an integrated microfluidic chip for nucleic acid detection. Different reaction reagents are respectively embedded in the liquid capsules. The reagents will not contaminate each other before the experimental operation, thereby ensuring the accuracy of the reaction. The chip is provided with a mixing pool, and the sample and the reaction reagent are fully mixed to ensure the stability of the subsequent constant temperature reaction. The mixed sample is centrifuged and injected into the reaction pool in sequence to ensure that the sample amount entering each reaction pool is uniform, thereby improving the stability and accuracy of the detection. A plurality of reaction pools are provided, and twelve sepsis resistance genes can be detected simultaneously, with a large detection throughput and high efficiency, thereby greatly reducing the average cost of detecting a single resistance gene. The present invention is provided with an internal standard solution, a negative control solution and a positive control solution, and can fully monitor the nucleic acid extraction and purification and isothermal amplification processes, thereby ensuring the accuracy of sample detection and preventing inaccurate detection results due to reagent problems. The samples used are blood, sputum and alveolar lavage fluid. Sputum and alveolar lavage fluid are two types of samples that often contain lumps, which affect the detection results. The present invention only requires a small amount of sample and liquefies the sample by using NaOH to reduce influencing factors. There are many interfering substances in the blood sample and the pathogen concentration is low, which will affect the detection results. The present invention specifically enriches the pathogens in the blood sample by using mannose binding lectin to increase the pathogen concentration, and optimizes the overall reaction system to improve the sensitivity of the detection. BRIEF DESCRIPTION OF THE DRAWINGS
[0024] In order to facilitate understanding by those skilled in the art, the present invention is further described below with reference to the accompanying drawings.
[0025] Figure 1 It is a schematic diagram of the overall structure of the chip of the present invention; Figure 2 It is the amplification curve diagram of twelve sepsis resistance genes and internal standard genes of the present invention; Description of main component symbols: In the figure: 1. Mixing pool; 2. Sample addition hole; 3. First liquid capsule; 4. Second liquid capsule; 5. Third liquid capsule; 6. Sample pool; 7. Adsorption column; 8. Waste liquid pool; 9. Internal standard pool; 10. Negative pool; 11. Reaction pool; 12. Reserved pool. DETAILED DESCRIPTION
[0026] The technical scheme of the present invention is explained and described in detail below in conjunction with the accompanying drawings and preferred specific embodiments, so that those skilled in the art can better understand the present invention and implement it. In the embodiments, unless otherwise specified, the instruments and reagents used are conventional instruments and reagents in the art.
[0027] Example 1
[0028] A primer composition for detecting sepsis resistance genes In this example, the known gene sequences of carbapenem-resistant genes: KPC, IMP, NDM, Oxa-48-like, VIM and GES, aminoglycoside-resistant genes: aac, aph, ant and armA, and methicillin-resistant genes: mecA and mecC were analyzed and compared to obtain their respective specific gene sequences, and primer sets were designed and optimized for the specific gene sequences, so that the twelve genes can be detected simultaneously under the same reaction conditions and all meet the requirements of high sensitivity and specificity, and also include detection primers for the internal standard gene HBB.
[0029] The specific nucleotide sequences of the designed primers are shown in the following table: Table 1: Primers for sepsis resistance gene detection and internal standard gene primer sequences
[0030] In Table 1 above, F3 represents the upstream outer primer used in the LAMP technology; B3 represents the downstream outer primer used in the LAMP technology; FIP represents the upstream inner primer used in the LAMP technology; BIP represents the downstream inner primer used in the LAMP technology; LF represents the upstream loop primer used in the LAMP technology; LB represents the downstream loop primer used in the LAMP technology.
[0031] Example 2
[0032] A sepsis resistance gene detection kit like Figure 1 Shown is the chip used in this embodiment.
[0033] The present embodiment is a sepsis resistance gene detection kit, comprising 6 chips, 5 mL of lysis solution, 0.5 mL of internal standard solution, 1 mL of negative control solution, 1 mL of positive control solution and 12 chip sealing films, the chip is provided with a plurality of reaction pools 11, each of which is embedded with one of the sepsis resistance gene detection primer sets.
[0034] The ratio of the detection primer set embedded in the reaction pool 11 is F3:B3:FIP:BIP:LF:LB, which is 1:1:8:8:3:3.
[0035] Reaction reagents are embedded in the chip, including freeze-dried proteinase K, 400 μL of the first cleaning solution, 400 μL of the second cleaning solution, 120 μL of the elution solution and isothermal amplification reaction freeze-dried balls.
[0036] The first cleaning solution was composed of 0.2 M sodium chloride NaCl and 60% isopropanol, the second cleaning solution was 80% anhydrous ethanol, and the eluent was 1×TE Buffer.
[0037] The isothermal amplification reaction freeze-dried ball is composed of 10 mM deoxyribonucleoside triphosphate dNTP, 5% bovine serum albumin BSA, 5 M magnesium sulfate MgSO4, 100 μM fluorescent dye, 5 M betaine and 8 U / μL Bst DNA polymerase, with a preparation ratio of 2:5:1:1:4:3, and the amplification concentration of Bst DNA polymerase is 0.3 U / μL.
[0038] The lysis buffer consisted of 100 mM ethylenediaminetetraacetic acid (EDTA), 5 M guanidine hydrochloride, 20% Tween-20, and 5% sodium dodecyl sulfate (SDS).
[0039] The internal standard solution was a glycerol bacterial solution containing the internal standard gene HBB fragment, the negative control solution was normal saline, and the positive control solution was a glycerol bacterial solution containing the carbapenem-resistant gene KPC fragment.
[0040] The kit comes with an internal standard solution, a negative control solution and a positive control solution, and is provided with an internal standard pool 9 and a negative pool 10. In a specific experiment, the nucleic acid extraction and constant temperature amplification process can be fully monitored to ensure the accuracy of sample detection and prevent inaccurate test results caused by reagent problems.
[0041] The sepsis resistance gene detection kit provided in this embodiment has a large detection throughput, high efficiency, strong specificity, high sensitivity, and convenient operation, and greatly reduces the average cost of detecting a single resistance gene.
[0042] Example 3
[0043] Methods for detecting sepsis resistance genes in samples: sputum or bronchoalveolar lavage fluid like Figure 1 The chip used in this embodiment is shown.
[0044] S1: Collect the patient's sputum in a sterile container. The sample volume should be no less than 1 mL after liquefaction with NaOH. S2: Take 200 μL of sample, add 10 μL of internal standard solution and 400 μL of lysis solution, and mix well; S3: The mixed sample is injected into the sample pool 6 of the chip through the sample injection hole 2, the chip sealing film is affixed, and the chip is placed in a fully automatic constant temperature nucleic acid amplification analyzer for extraction, purification, amplification and detection. The program is set to run automatically, lyse, extract, purify, and then amplify at 63°C for 40 min; S4: The fully automatic constant temperature nucleic acid amplification analyzer collects the fluorescence signals of each reaction pool in real time, draws an amplification curve, and determines the positive or negative nature of the test sample based on the detection time Dt value of the amplification curve.
[0045] The Dt value is the abscissa value of the intersection of the S-type amplification curve of the drug-resistant gene and the internal standard gene with the threshold line, which is the Dt value to determine the positive or negative nature of the test sample.
[0046] The detection method provided in this embodiment is easy to operate, has low requirements on equipment, has high detection efficiency, and can quickly identify drug-resistant genes within 1 hour, which is of great significance for clinical treatment.
[0047] Example 4
[0048] Method for detecting drug-resistant genes in sepsis samples: blood like Figure 1 The chip used in this embodiment is shown.
[0049] S1: Collect 5 mL of the patient's blood in a sterile container, add the blood sample to a filter collection column coated with mannose-binding lectin, remove the waste liquid after filtration, and enrich the pathogens in the blood sample in the lectin. Add 400 μL of lysis solution to the collection column to lyse the enriched pathogen sample; S2: Add 10 μL of internal standard solution to the enriched pathogen sample and mix well; S3: The mixed sample is injected into the sample pool 6 of the chip through the sample injection hole 2, the chip sealing film is affixed, and the chip is placed in a fully automatic constant temperature nucleic acid amplification analyzer for extraction, purification, amplification and detection. The program is set to run automatically, lyse, extract, purify, and then amplify at 63°C for 40 min; S4: The fully automatic constant temperature nucleic acid amplification analyzer collects the fluorescence signals of each reaction in real time, draws an amplification curve, and determines the positive or negative nature of the test sample based on the Dt value of the amplification curve.
[0050] Example 5
[0051] Working principle and usage process of the chip Reference Figure 1 , inject the sample into the sample pool 6 of the chip through the sample injection hole 2, and the subsequent processes are all carried out in the fully automatic constant temperature nucleic acid amplification analyzer; The sample was dissolved in the embedded freeze-dried proteinase K, the chip was rotated back and forth to mix, and then heated at 95°C and allowed to lyse for 5 min; The device controls the chip to centrifuge clockwise at 8000 rpm for 30 s, and the sample lysate passes through the adsorption column 7 and flows into the waste liquid pool 8; The first liquid capsule 3 is pressed down to puncture its bottom, releasing 400 μL of the first cleaning solution, and the chip is centrifuged clockwise at 8000 rpm for 30 s. The first cleaning solution passes through the adsorption column 7 and flows into the waste liquid pool 8; The second liquid capsule 4 is pressed down to puncture its bottom, releasing 400 μL of the second cleaning solution, and the chip is centrifuged clockwise at 8000 rpm for 30 s. The second cleaning solution passes through the adsorption column 7 and flows into the waste liquid pool 8. The chip is centrifuged clockwise at high speed at 14000 rpm for 30 s. The residual cleaning solution passes through the adsorption column 7 and flows into the waste liquid pool 8. The third liquid capsule 5 is pressed down to puncture its bottom, releasing 120 μL of eluent, and the chip is centrifuged counterclockwise at 8000 rpm for 30 s. The eluent passes through the adsorption column 7 and flows into the mixing pool 1; The isothermal amplification reaction freeze-dried balls in the mixing pool 1 were shaken to dissolve and mix, and the mixture was reciprocated at 1000 rpm for 3 times. Then the chip was centrifuged counterclockwise at 8000 rpm for 60 s. The sample reaction solution in the mixing pool 1 was filled with the reserved pool 12, reaction pool 11, negative pool 10 and internal standard pool 9 in sequence. A heating temperature zone was set under the internal standard pool 9, negative pool 10, reaction pool 11 and reserved pool 12. The sample reaction solution was subjected to isothermal nucleic acid amplification in each pool, and the amplification conditions were 63°C for 40 min.
[0052] In the chip of this embodiment, different reaction reagents are respectively embedded in the liquid capsules, and the reagents will not contaminate each other before the experimental operation, thereby ensuring the accuracy of the reaction. The chip is provided with a mixing pool 1, and the sample and the reaction reagent are fully mixed to ensure the stability of the reaction. The mixed sample is centrifuged and injected into each pool in sequence to ensure that the sample amount entering each pool is uniform, thereby improving the accuracy of the detection.
[0053] Example 6
[0054] Specificity experiments based on Figure 1 The chip shown in the figure was used to perform specific detection experiments on each sepsis resistance gene. 200 μL of sample solutions containing carbapenem-resistant genes: KPC, IMP, NDM, Oxa-48-like, VIM and GES, aminoglycoside-resistant genes: aac, aph, ant and armA, and methicillin-resistant genes: mecA and mecC were taken, mixed with 10 μL of internal standard solution and 400 μL of lysis solution, and the mixture was injected into the sample pool 6 of the chip through the sample well 2. The chip was sealed with a chip film and placed in a fully automatic constant temperature nucleic acid amplification analyzer for nucleic acid extraction, purification, amplification and detection. The program automatically ran lysis, extraction, purification, and then amplification at 63°C for 40 min.
[0055] The amplification results are as follows Figure 2 As shown in Table 2, no amplification reaction occurred in the negative pool 10, indicating that the reaction system was not contaminated and the amplification reaction was normal. The amplification of the internal standard gene in the internal standard reaction pool 9 showed an "S"-shaped amplification curve, indicating that the amplification of the internal standard gene was normal. Each corresponding drug-resistant gene in each reaction pool 11 showed an "S"-shaped amplification curve, and the remaining drug-resistant genes were not amplified, indicating that there was no cross-reaction between the drug-resistant genes and the specificity was good.
[0056] The result analysis is performed through the Dt value of the amplification curve. The Dt value is the horizontal coordinate value of the intersection point of the S-type amplification curve of the drug-resistant gene and the internal standard gene with the set threshold line. The Dt value is used to determine the positivity of the test sample. When the test sample is positive: the amplification curve of its reaction pool intersects with the set threshold line; when the test sample is negative: the reaction pool does not amplify and has no intersection with the set threshold line.
[0057] Table 2 Results of primer-specific amplification of each drug resistance gene
[0058] Among them, "+" indicates positive amplification, and "-" indicates negative amplification.
[0059] Sensitivity experiment The sample solutions containing carbapenem-resistant genes: KPC, IMP, NDM, Oxa-48-like, VIM and GES, aminoglycoside-resistant genes: aac, aph, ant and armA, and methicillin-resistant genes: mecA and mecC were diluted to 10 5 , 10 4 , 10 3 , 10 2 , 10 1 Copies / mL concentration.
[0060] Take 200 μL of the sample solutions of different concentrations, 10 μL of the internal standard solution and 400 μL of the lysis solution, mix them to make a mixed solution, and then inject them into the sample pool 6 of the chip through the sample injection hole 2. The chip is sealed with a film and placed in a fully automatic constant temperature nucleic acid amplification analyzer for nucleic acid extraction, purification, amplification and detection. The program automatically runs lysis, extraction, purification, and then amplification at 63°C for 40 min.
[0061] The amplification results are shown in Table 3. No amplification reaction occurred in the negative pool 10, indicating that the reaction system was not contaminated and the amplification reaction was normal. The internal standard gene in the internal standard pool 9 showed an "S"-shaped amplification curve, indicating that the internal standard gene was amplified normally. The carbapenem-resistant genes: KPC, IMP, NDM, Oxa-48-like, VIM and GES, the aminoglycoside-resistant genes: aac, aph, ant and armA, and the methicillin-resistant genes: mecA and mecC were detected at a concentration of 10 2 copies / mL, all amplified normally. 1 When the minimum sensitivity concentration was 10, the carbapenem-resistant genes KPC and GES were not amplified, the carbapenem-resistant genes IMP, Oxa-48-like and the methicillin-resistant gene mecC were not fully amplified, and the remaining genes were amplified normally, indicating that the minimum sensitivity concentration should be set to 10 2 copies / mL.
[0062] Table 3 Table of sensitivity amplification Dt values of primers for each drug resistance gene
[0063] Among them, “-” means no amplification and negative.
[0064] When the present invention is used: The above description is only a preferred embodiment of the present invention and does not limit the present invention in any form. Although the present invention has been disclosed as a preferred embodiment as above, it is not used to limit the present invention. Any technical personnel in this field can make some changes or modify the technical contents disclosed above into equivalent embodiments without departing from the scope of the technical solution of the present invention. However, any brief modifications, equivalent changes and modifications made to the above embodiments based on the technical essence of the present invention without departing from the content of the technical solution of the present invention are still within the scope of the technical solution of the present invention.
Claims
1. A primer composition for detecting sepsis resistance genes, characterized in that: A detection primer set comprising carbapenem-resistant genes: KPC, IMP, NDM, Oxa-48-like, VIM and GES, aminoglycoside-resistant genes: aac, aph, ant and armA, and methicillin-resistant genes: mecA and mecC, wherein the detection primer set is composed of one or more of an upstream loop primer LF or a downstream loop primer LB, except for the armA and mecC detection primer sets, which do not include the LF and the LB, an upstream outer primer F3, a downstream outer primer B3, an upstream inner primer FIP and a downstream inner primer BIP, and the nucleotide sequence is as follows: KPC detection primer set: SEQ ID NO: 1 to SEQ ID NO: 5; IMP detection primer set: SEQ ID NO: 6 to SEQ ID NO: 10; NDM detection primer set: SEQ ID NO: 11 to SEQ ID NO: 16; Oxa-48-like detection primer set: SEQ ID NO: 17 to SEQ ID NO: 21; VIM detection primer set: SEQ ID NO: 22 to SEQ ID NO: 26; GES detection primer set: SEQ ID NO: 27 to SEQ ID NO: 31; aac detection primer set: SEQ ID NO: 32 to SEQ ID NO: 36; aph detection primer set: SEQ ID NO:37 to SEQ ID NO:41; Ant detection primer set: SEQ ID NO: 42 to SEQ ID NO: 47; armA detection primer set: SEQ ID NO:48 to SEQ ID NO:51; mecA detection primer set: SEQ ID NO: 52 to SEQ ID NO: 56; mecC detection primer set: SEQ ID NO:57 to SEQ ID NO:
60.
2. A primer composition for detecting sepsis resistance gene according to claim 1, characterized in that: It also includes internal standard gene HBB detection primers, the nucleotide sequences of which are as follows: SEQ ID NO:61 to SEQ ID NO:
66.
3. A sepsis resistance gene detection kit, characterized in that: The invention comprises 6 chips, 5 mL of lysis solution, 0.5 mL of internal standard solution, 1 mL of negative control solution, 1 mL of positive control solution and 12 chip sealing films, wherein the chip is provided with a plurality of reaction pools, each of which is embedded with one of the primer compositions for detecting sepsis resistance genes according to claim 1.
4. A sepsis resistance gene detection kit according to claim 3, characterized in that: The ratio of the detection primer set embedded in the reaction pool is F3:B3:FIP:BIP:LF:LB, which is 1:1:5~8:5~8:3:
3.
5. A sepsis resistance gene detection kit according to claim 3, characterized in that: The chip is embedded with reaction reagents, which include freeze-dried proteinase K, 100-400 μL of a first cleaning solution, 100-400 μL of a second cleaning solution, 60-120 μL of an elution solution, and a constant temperature amplification reaction freeze-dried ball.
6. A sepsis resistance gene detection kit according to claim 5, characterized in that: The first cleaning solution is composed of 0.01-0.2 M sodium chloride NaCl and 20-60% isopropanol, the second cleaning solution is 40-80% anhydrous ethanol, and the eluent is 1×TE Buffer.
7. A sepsis resistance gene detection kit according to claim 5, characterized in that: The isothermal amplification reaction freeze-dried ball consists of 10 mM deoxyribonucleoside triphosphate dNTP, 5% bovine serum albumin BSA, 5 M magnesium sulfate MgSO4, 100 μM fluorescent dye, 5 M betaine and 8 U / μL BstDNA polymerase, and the preparation ratio is 2:3~5:1:1:2~4:1~3. The amplification concentration of the Bst DNA polymerase is 0.3~3U / μL.
8. A sepsis resistance gene detection kit according to claim 3, characterized in that: The lysate is composed of 50-100 mM ethylenediaminetetraacetic acid (EDTA), 3-5 M guanidine hydrochloride, 10-20% Tween-20, and 1-5% sodium dodecyl sulfate (SDS).
9. A sepsis resistance gene detection kit according to claim 3, characterized in that: The internal standard solution is a glycerol bacterial solution containing an internal standard gene HBB fragment, the negative control solution is physiological saline, and the positive control solution is a mixed glycerol bacterial solution containing one or more of the carbapenem-resistant genes: KPC, IMP, NDM, Oxa-48-like, VIM and GES, the aminoglycoside-resistant genes: aac, aph, ant and armA, and the methicillin-resistant genes: mecA and mecC fragments.
Citation Information
Patent Citations
Animal-derived food pathogen identification and drug-resistant and toxic gene detection composite chip
CN105950732A
Drug resistant gene microfluidic chip rapid detection kit and detection method
CN107475364A
LAMP primer for detecting five carbapenemase genes of enterobacter and subtypes thereof and kit thereof
CN112458153A
Primers, probes, kit and method for detecting six main carbapenemase genes
CN113444820A
Primer composition for detecting sepsis pathogen, nucleic acid detection kit and detection method thereof
CN114807399A
Cited By
Integrated method for bacterium enrichment and sample preparation based on Coulter counting
CN120366157A
